Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

25.33 -0.73 (-2.80%)
Streaming Delayed Price Updated: 11:08 AM EST, Jan 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by... 
Via MarketMinute
News headline image
Olema Insider Sells $8 Million in Shares After 300% Stock Surge ↗
Focused on therapies for women's cancers, this clinical-stage biotech reported a significant insider sale amid a year of sharp stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Olema Oncology
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
On Thursday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Biotech Stock Gets Booted in Latest Fund Update ↗
Bain Capital sold its entire stake in Nuvalent stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗
Bain Capital completely exited its position in Disc Medicine stock during the third quarter 
Via The Motley Fool
News headline image
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Olema Oncology
Via GlobeNewswire
News headline image
Which stocks are moving on Tuesday? ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Which stocks are most active on Tuesday? ↗
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
News headline image
Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Top movers in Tuesday's session ↗
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock. 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
News headline image
Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile. 
Via Benzinga
News headline image
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗
The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow. 
Via Investor's Business Daily
Topics Government
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.